Evaxion Biotech remains a high-risk, clinical-stage entity whose valuation is tethered to the success of its AI-driven PIONEER platform rather than consistent commercial performance. The company's reliance on lumpy milestone payments, evidenced by a 148.3% rev...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Profitability This table compares Evaxion A/S and Nektar
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and less side effects than current treatments Initial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026 COPENHAGEN, Denmark, September 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI- Immunology™ platform, has begun the application of the platform in autoimmune diseases thereby expanding the company's therapeutic focus and achieving another company milestone for 2026.
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.
Benchmark EVAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Evaxion Biotech A/S (EVAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.27 | $20.66M | -2.70 | 125.12% | -102.38% | -100.18% | — | |
| $0.94 | $15.76M | 1.84 | -33.66% | 397.84% | 34.15% | — | |
| $37.29 | $7.7B | -13.46 | — | -7585.86% | -69.59% | — | |
| $60.97 | $2.02B | -6.27 | -43.89% | -287.84% | -37.99% | — | |
| $10.64 | $4.75B | -9.76 | 60.6% | -89.09% | -40.51% | — | |
| $152.67 | $189.55B | 22.52 | 2.39% | -10.64% | -16.35% | — |
Evaxion Biotech A/S (EVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Evaxion Biotech A/S (EVAX) stock FAQ — growth, dividends, profitability & financials explained
Evaxion Biotech A/S (EVAX) reported $7.5M in revenue for fiscal year 2025.
Evaxion Biotech A/S (EVAX) grew revenue by 125.1% over the past year. This is strong growth.
Evaxion Biotech A/S (EVAX) reported a net loss of $8.7M for fiscal year 2025.
Evaxion Biotech A/S (EVAX) has a return on equity (ROE) of -100.2%. Negative ROE indicates the company is unprofitable.
Evaxion Biotech A/S (EVAX) had negative free cash flow of $6.7M in fiscal year 2025, likely due to heavy capital investments.
